{"meshTags":["ras Proteins","Colorectal Neoplasms","Receptor, Epidermal Growth Factor","Biomarkers, Tumor","Genetic Testing","Treatment Outcome","Proto-Oncogene Proteins p21(ras)","Patient Selection","Proto-Oncogene Proteins","Phosphatidylinositol 3-Kinases","Precision Medicine","Protein Kinase Inhibitors","Drug Resistance, Neoplasm","Humans","Proto-Oncogene Proteins B-raf","Antineoplastic Agents","Genes, ras","Mutation"],"meshMinor":["ras Proteins","Colorectal Neoplasms","Receptor, Epidermal Growth Factor","Biomarkers, Tumor","Genetic Testing","Treatment Outcome","Proto-Oncogene Proteins p21(ras)","Patient Selection","Proto-Oncogene Proteins","Phosphatidylinositol 3-Kinases","Precision Medicine","Protein Kinase Inhibitors","Drug Resistance, Neoplasm","Humans","Proto-Oncogene Proteins B-raf","Antineoplastic Agents","Genes, ras","Mutation"],"genes":["EGFR"],"publicationTypes":["Letter","Comment"],"title":"Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?","pubmedId":"21051017"}